Here’s what happened last week in the GLP1 ecosystem: 📑 Orforglipron Phase 3 trial results landed 📢 TEVA Pharmaceuticals announced FDA approval for weight loss with Liraglutide 🎤 Meghan Trainor has been in the news after a GLP1 transformation 🎾 Serena Williams has shared her GLP1 story Go deeper, read more Here are
drug:orforglipron
We take a look at the most recent set of results from Orforglipron, the oral GLP1 from Eli Lilly
drug:cagrisema
We take a look at the recent results for CagriSema, and see how it tracks against other GLP1s
chemical:semaglutide
Recent reports of kidney injuries have caused a change in requirements for GLP1 labeling. We dive into the actual risk and what you can do about it.
drug:mounjaro
Trulicity and Mounjaro go head to head, in a clinical trial that finally puts to bed the question of which is better.
politics
GLP1s might be covered under Medicare/medicaid again. The Trump administration introduces a new experiment under the CMMI.
drug:phentermine
Reports of combining GLP1s with Phentermine suggest superior results. What is Phentermine and how can it be used with GLP1s?
Yet another manufacturer signs up to produce generic Semaglutide for much of the world (ex. EU and USA) - what does Dr. Reddy's have planned?
Hims is going to start selling generic Semaglutide in 2026, long before US patents expire. How?
Novo Nordisk is looking to introduce a new higher dosage of Semaglutide (Wegovy) -- we take a look at the studies they *didn't* submit.
Novo Nordisk expanded their collaboration with Weight Watchers, offering an introductory price of $299
CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).
Why are so few people able to stay on GLP1s for 3 years? We dig into the analysis & report by Prime Therapeutics.
Reflection on the ACC's endorsement of GLP1s as a first-line approach to weight management and improving cardiovascular outcomes.
We explore the new GLP1 risk factor for macular degeneration (nAMD) that has been reported in a study published to JAMA.
MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.
Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.